SUMMARY In a population based series of 4070 children with acute lymphoblastic leukaemia treated in Britain during 1971-82, the five year survival rate improved from 37% for those treated in 1971-3 to 66% in 1980-2. During the same period there was an increase in the proportion of children included in the Medical Research Council trials and an increase in the proportion who were treated at centres with an average of at least six new patients per year. Survival rates were significantly higher for children who were included in the trials than for those who were not. Among children not in the trials, the survival rate was highest at centres treating at least six children per year and lowest at those with fewer than one per year. The increase in the numbers of children treated according to standardised protocols, particularly within controlled clinical trials, has had a major impact on the mortality from childhood acute lymphoblastic leukaemia.
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In Britain during 1971-82, with a population of about 13 000 000 children below age 15 The effects of inclusion in the trials and size of treatment centre were very noticeable during the few months immediately after diagnosis, and it might be argued that this reflects some selection bias; however, when patients who had died within three months of diagnosis were excluded from the analysis, the differences between trial and non-trial patients and between those at different categories of treatment centre were still highly significant.
Although the great majority of deaths from acute lymphoblastic leukaemia in children occur within five years of diagnosis, there is a substantial risk of death beyond this time. So far 248 deaths have been recorded among the 1835 children surviving at least five years up to the end of December 1986. The subsequent survival rate for those who survived five years did not differ as between trial and non-trial patients. This rate was, however, significantly higher for centres in group A than for groups B and C (X2=6-34 on 1 df, stratified by age and calendar period of diagnosis). Of the 248 patients who died after five years or more 189 (76%) had suffered a first relapse at less than five years from diagnosis; 26 (10%) had a first relapse later than five years (maximum nine years); seven (3%) were in first remission from acute lymphoblastic leukaemia at the time of death; no information on time to first relapse was available for the remaining 26 (10%).
As yet only 16 second primary tumours have been observed in the series; 13 of these 16 patients have died. There was no obvious association of the risk of developing a second primary tumour with whether children were included in the trials or with treatment centre size, but this result should be treated with caution because of the small number of second primary tumours as a proportion of the total series.
Discussion
There is considerable interest in questions concerning the centralisation of treatment for childhood cancer and leukaemia. Over the past 20 years there has been a continuing trend towards such centralisation in the United Kingdom; some indication of this is given in table 2 . There has been very little published evidence on the effects on the survival rate for childhood acute lymphoblastic leukaemia of such centralisation-that is, of treatment at specialist centres or within controlled clinical trials. In the mid 1960s, when survival was generally extremely poor, it was found that children treated at specialist centres were more likely to survive. 12 More recently, an analysis of over 300 children with acute lymphoblastic leukaemia from the population based Greater Delaware Valley Pediatric Tumor Registry in the United States showed significant advantages in survival for patients treated at specialist cancer centres and for those who were treated according to standardised protocols. 13 The results of the present analyses agree with these findings. In the early 1970s there were large differences in survival rates between centres treating many patients and those where only a few were treated. These differences diminished in more recent years. To some extent this may be explained by assuming that some of the less successful smaller centres gave up treating children with acute lymphoblastic leukaemia during this period.
Also, of course, even the smallest centres which did continue to treat some of these children will have had a larger total number of patients by the 1980s.
In addition to the overall pattern of higher survival rates at treatment centres seeing larger numbers of patients, there was considerable variation in survival between individual major centres. Among the 12 centres in group A, there was no association between survival rates and size of centre, but the five year survival rates of these centres ranged from 45% to 70%. Some of this variation is probably explained by random differences in the proportions of children with good or poor prognostic features at individual centres. Nevertheless, detailed analysis of the rates achieved at one centre suggests that some of the variation may be due to differences in the application of apparently similar treatment protocols.
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Overall the survival rate at the group B centres was lower than for group A and higher than for group C, but within group B there was no difference in rates between those centres with one, two, three, or four patients per year.
The effects on the survival rate of inclusion in the trials and size of treatment centre both persisted beyond three months from diagnosis. This suggests that the differences in survival rates cannot be explained solely by patients more frequently failing to achieve remission outside the trials and at minor centres.
The risk of first relapse after the completion of treatment generally appears to be low,'2 15 During 1980-4 there were 1558 children treated for acute lymphoblastic leukaemia, of whom 51% were included in the Medical Research Council trials. The great majority (66%) were treated at group A centres, with 28% at group B, and only 5% at group C. The overall five year survival rate was 68%. Within the trials the five year survival rate was 72%, compared with 64% outside the trials, and the difference between the survival curves was highly significant (X2= 100 on 1 df, p<0.001, allowing for age at diagnosis). For trial and non-trial patients combined, the five year survival rates at centres in groups A and B were very similar, 69% and 68% respectively, but the rate in group C was only 53%. There was no association between the survival rate and the number of patients per year within group B. Within the trials the survival rate was very similar at centres in groups A (72%), B (71%), and C (68%). For non-trial patients, the rates were 64%, 66%, and 48% respectively. These results show the continuing importance of treatment according to standardised protocols, particularly within nationally organised trials, for the achievement of the best survival rates in childhood acute lymphoblastic leukaemia. Since the 1970s, the survival rates at centres treating between one and six new patients per year have become very similar to those obtained at the largest centres, but those for children treated at centres with fewer than one new patient per year and not included in the UKALL trials remained considerably poorer. 
